Clinical Trial Update: Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing. [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on retention and duration of activity of SPL7013 (VivaGel) after vaginal dosing, involving Phase 1 and Phase 2 studies, completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Herpes
• HIV Infections

Drugs mentioned

• VivaGel (SPL7013)

Snippet

Sponsor: Starpharma Pty Ltd | Conditions: HIV Infections, HSV-2 Genital Herpes | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2012-08-14